The strong association between ERα and PR expression and Type I endometrioid carcinoma as compared with Type II non-endometrioid carcinoma [32], explains the effectiveness of progestin therapy for Type I endometrioid carcinoma. This evidence concerns the gene ESR1 and endometrioid adenocarcinoma.